Skip to main content
Figure 2 | Journal of Translational Medicine

Figure 2

From: Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I)

Figure 2

Dose escalation design. Three patients will be treated with the starting dose. If no DLT occurs, the next cohort will be treated with the next MAPC dose level. If one DLT occurs in a cohort, a second cohort of 3 patients will be treated with the same MAPC dose level. The study will be stopped if more than one DLT event is recorded after enrolling at most 6 patients.

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us